| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1225 | 2020 |
| Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, ... New England Journal of Medicine 387 (3), 217-226, 2022 | 387 | 2022 |
| KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo+ chemotherapy for previously untreated locally recurrent inoperable or … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... Journal of Clinical Oncology 38 (15_suppl), 1000-1000, 2020 | 198 | 2020 |
| KEYNOTE-355 Investigators Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... Lancet 396 (10265), 1817-1828, 2020 | 56 | 2020 |
| The relationship of ectopic lipid accumulation to cardiac and vascular function in obesity and metabolic syndrome FL Ruberg, Z Chen, N Hua, S Bigornia, Z Guo, K Hallock, H Jara, ... Obesity 18 (6), 1116-1121, 2010 | 49 | 2010 |
| LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab+ chemotherapy vs placebo+ chemotherapy for metastatic TNBC J Cortés, DW Cescon, HS Rugo, SA Im, MM Yusof, C Gallardo, O Lipatov, ... Annals of Oncology 32, S1289-S1290, 2021 | 31 | 2021 |
| Groupwise dimension reduction via envelope method Z Guo, L Li, W Lu, B Li Journal of the American Statistical Association 110 (512), 1515-1527, 2015 | 26 | 2015 |
| Pharmacokinetic interactions between elbasvir/grazoprevir and immunosuppressant drugs in healthy volunteers HP Feng, L Caro, CM Fandozzi, Z Guo, J Talaty, D Wolford, D Panebianco, ... The Journal of Clinical Pharmacology 58 (5), 666-673, 2018 | 23 | 2018 |
| Pharmacokinetics of Co-Administered HCV Protease Inhibitor MK-5172 and NS5A Inhibitor MK-8742 in Volunteers with End-Stage Renal Disease on Hemodialysis or Severe Renal … WW Yeh, L Caro, Z Guo, HP Feng, HU Davis, M Kozisek, D Stypinski, ... Hepatology 60, 1137A, 2014 | 20 | 2014 |
| Pharmacokinetic interactions between the hepatitis C virus inhibitors elbasvir and grazoprevir and HIV protease inhibitors ritonavir, atazanavir, lopinavir, and darunavir in … HP Feng, L Caro, C Fandozzi, X Chu, Z Guo, J Talaty, D Panebianco, ... Antimicrobial agents and chemotherapy 63 (4), 10.1128/aac. 02142-18, 2019 | 19 | 2019 |
| No clinically meaningful pharmacokinetic interactions between HCV inhibitors Grazoprevir/Elbasvir with Tacrolimus, Mycophenolate Mofetil, and Prednisone, but Cyclosprine … WW Yeh, HP Feng, KM Dunnington, NC Marricco, L Caro, Z Guo, ... Hepatology 62, 570A-571A, 2015 | 17 | 2015 |
| Pharmacokinetic Interactions Between the HCV Protease Inhibitor MK-5172 and Ritonavir-Boosted HIV Protease Inhibitors (Atazanavir, Lopinavir, Darunavir) in Healthy nVolunteers: 487 L Caro, JE Talaty, Z Guo, IP Fraser, HU Davis, T O'Reilly, WW Yeh, ... Hepatology 58, 442A-443A, 2013 | 16 | 2013 |
| Abstract GS3-01: additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for … HS Rugo, P Schmid, DW Cescon, Z Nowecki, SA Im, MM Yusof, ... Cancer Research 81 (4_Supplement), GS3-01-GS3-01, 2021 | 15 | 2021 |
| KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (PBO)+ chemo for previously untreated, locally recurrent … J Cortés, Z Guo, V Karantza, G Aktan Journal of Clinical Oncology 36 (5_suppl), TPS18-TPS18, 2018 | 15 | 2018 |
| Mice Deficient in Phosphofructokinase‐M Have Greatly Decreased Fat Stores L Getty‐Kaushik, JC Viereck, JM Goodman, Z Guo, NK LeBrasseur, ... Obesity 18 (3), 434-440, 2010 | 15 | 2010 |
| Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies J Kobie, Z Guo, CR Cho, K Menzel, JB McCrea, R Blanchard, PM Shaw The Journal of Clinical Pharmacology 59 (9), 1236-1243, 2019 | 14 | 2019 |
| Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and Midazolam, Pitavastatin, and Atorvastatin in Healthy Volunteers: 477 L Caro, JE Talaty, Z Guo, C Reit-mann, IP Fraser, R Evers, D Swearingen, ... Hepatology 58, 437A-438A, 2013 | 14 | 2013 |
| Effect of hepatic impairment on the pharmacokinetics of grazoprevir, a hepatitis C virus protease inhibitor L Caro, L Wenning, Z Guo, IP Fraser, C Fandozzi, J Talaty, D Panebianco, ... Antimicrobial agents and chemotherapy 61 (12), 10.1128/aac. 00813-17, 2017 | 13 | 2017 |
| Pharmacokinetics of coadministered HCV protease inhibitor grazoprevir (MK-5172) and NS5A inhibitor elbasvir (MK-8742) in volunteers with end-stage renal disease on hemodialysis … WW Yeh, L Caro, Z Guo, HP Feng, H Davis, M Kozisek, D Stypinski, ... 65th annual meeting of the American association for the study of liver …, 2014 | 12 | 2014 |
| No meaningful pharmacokinetic interaction between HCV protease inhibitor MK-5172 and Tenofovir or Raltegravir W Yeh, I Fraser, L Caro, J Talaty, Z Guo, H Davis, SP Youngberg, ... Conference on Retroviruses and Opportunistic Infections, 3-6, 2014 | 12 | 2014 |
